JNJ241011C160000
- 1.06
- -0.12-10.17%
Johnson & Johnson Newsroom
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Johnson & Johnson Analyst Ratings
Verb Surgical Granted US Patent # 12,108,928 B2 For MACHINE-LEARNING-BASED VISUAL-HAPTIC SYSTEM FOR ROBOTIC SURGICAL PLATFORMS
Johnson & Johnson's (NYSE:JNJ) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $178
Goldman Sachs Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $162
Express News | J&J : RBC Raises Target Price to $178 From $175
Johnson & Johnson (JNJ.US) has stopped the Phase II study of bladder cancer therapy TAR-200.
Johnson & Johnson has announced that due to disappointing data, the company has halted the Phase II study of TAR-200, a therapy used to treat Muscle-Invasive Bladder Cancer (MIBC) patients.
J&J Discontinues Phase 2 Study for Bladder Cancer Drug TAR-200
JNJ Should Continue Higher at Least to Complete a Pullback
Express News | J&J - on Target for U.S. FDA Filing of Tar-200 Monotherapy (Sunrise-1) in Non-Muscle Invasive Bladder Cancer in Early 2025
Express News | J&J: Sunrise-2 Was Discontinued for Not Showing Superiority Versus Chemoradiation
Express News | Johnson & Johnson Statement on Sunrise-2 Study
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
Sector Update: Health Care Stocks Steady Late Afternoon
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Johnson & Johnson (NYSE:JNJ) Is a Favorite Amongst Institutional Investors Who Own 72%
Johnson & Johnson Halts Mid-stage Study for Dengue Antiviral
Express News | J&J: No Safety Issues Identified to Date in Phase 2 Field Study(Nct05201794)
Express News | J&J - Decision to Discontinue Study Part of a Strategic Reprioritization of Company’s Communicable Diseases R&D Portfolio.